Actinium Pharmaceuticals, Inc. (NYSE:ATNM) has a beta value of 1.8 and has seen 6,426,081 shares traded in the recent trading session. The company, currently valued at $164.74 Million, closed the recent trade at $0.41 per share which meant it lost -$0.02 on the day or -4.26% during that session. The ATNM stock price is -58.29% off its 52-week high price of $0.649 and 61.71% above the 52-week low of $0.157. If we look at the company’s 10-day average daily trading volume, we find that it stood at 30.69 Million shares traded. The 3-month trading volume is 21.96 Million shares.

The consensus among analysts is that Actinium Pharmaceuticals, Inc. (ATNM) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 3 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.01.

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) trade information

Despite being -4.26% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Aug 04 when the ATNM stock price touched $0.6054 or saw a rise of 33.1%. Year-to-date, Actinium Pharmaceuticals, Inc. shares have moved 86.04%, while the 5-day performance has seen it change -32.5%. Over the past 30 days, the shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) have changed 9.76%. Short interest in the company has seen 4.31 Million shares shorted with days to cover at 0.2.

Wall Street analysts have a consensus price target for the stock at $2.25, which means that the shares’ value could jump 448.78% from current levels. The projected low price target is $1.5 while the price target rests at a high of $3. In that case, then, we find that the current price level is +631.71% off the targeted high while a plunge would see the stock lose 265.85% from current levels.

Actinium Pharmaceuticals, Inc. (ATNM) estimates and forecasts

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +30.5% over the past 5 years. Earnings growth for 2020 is a modest +34.2%.

Actinium Pharmaceuticals, Inc. (NYSE:ATNM)’s Major holders

Insiders own 0.9% of the company shares, while shares held by institutions stand at 13.9% with a share float percentage of 14.03%. Investors are also buoyed by the number of investors in a company, with Actinium Pharmaceuticals, Inc. having a total of 45 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 4.55 Million shares worth more than $882.58 Thousand. As of March 30, 2020, Vanguard Group, Inc. (The) held 1.15% of shares outstanding.

The other major institutional holder is Blackrock Inc., with the holding of over 2.01 Million shares as of March 30, 2020. The firm’s total holdings are worth over $389.46 Thousand and represent 0.51% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of March 30, 2020, the former fund manager holds about 0.77% shares in the company for having 3033390 shares of worth $588.48 Thousand while later fund manager owns 1.4 Million shares of worth $270.8 Thousand as of March 30, 2020, which makes it owner of about 0.35% of company’s outstanding stock.